Why the study?
Allograft rejection remains the major hurdle in lung transplantation despite modern immunosuppressive treatment, with B cells increasingly recognized as modulators of alloimmunity and tolerance.
B cells play a complex, heterogeneous role in lung allograft rejection, presenting a potential target for future immunosuppressive therapies.
Answers are grounded in this paper and cite their sources.
B-cell modulation remains investigational in lung transplantation; this review leaves open the balance between rejection promotion and tolerance induction.
Allograft rejection remains the major hurdle in lung transplantation despite modern immunosuppressive treatment. As part of the alloreactive process, B cells are increasingly recognized as modulators of alloimmunity and initiators of a donor-specific humoral response. In chronically rejected lung allografts, B cells contribute to the formation of tertiary lymphoid structures and promote local alloimmune responses. However, B cells are functionally heterogeneous and some B cell subsets may promote alloimmune tolerance. In this review, we describe the current understanding of B-cell-dependent mechanisms in pulmonary allograft rejection and highlight promising future strategies that employ B cell-targeted therapies.
No takes yet. Share an insight, caveat, or question.
Ohm et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: